Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
Sacituzumab govitecan led to significantly longer progression-free survival than chemotherapy among patients with advanced triple-negative breast cancer who were not candidates for treatment with PD-1 or PD-L1 inhibitors. The incidence of adverse events of grade 3 or higher with sacituzumab govitecan was similar to that with chemotherapy, but adverse events were common. (Funded by Gilead Sciences; ASCENT-03 ClinicalTrials.gov number, NCT05382299.).
Authors
- Eriko Tokunaga (ORCID: https://orcid.org/0000-0002-1640-5315)
- Catherine Lai (ORCID: https://orcid.org/0000-0001-8861-0281)
- Roberto Hegg (ORCID: https://orcid.org/0000-0002-6453-8155)
- Kevin Punie (ORCID: https://orcid.org/0000-0002-1162-7963)
- Joohyuk Sohn (ORCID: https://orcid.org/0000-0002-2303-2764)
- Adam Brufsky (ORCID: https://orcid.org/0000-0001-8080-7960)
- Alessandra Fabi (ORCID: https://orcid.org/0000-0002-0758-8033)
- Javier Cortés (ORCID: https://orcid.org/0000-0001-7623-1583)
- Mafalda Oliveira (ORCID: https://orcid.org/0000-0001-9152-8799)
- Sara A. Hurvitz (ORCID: https://orcid.org/0000-0001-7808-7191)
- Sara M. Tolaney (ORCID: https://orcid.org/0000-0002-5940-8671)
- Natalya Vaksman
- Andreas Schneeweiß (ORCID: https://orcid.org/0000-0002-2429-4512)
- Xinrui Zhang (ORCID: https://orcid.org/0000-0003-0556-0157)
- Yeon Hee Park (ORCID: https://orcid.org/0000-0003-4156-9212)
- Carlos H. Barrios (ORCID: https://orcid.org/0000-0001-6021-667X)
- T. Valdez
Institutions
- Hebron University (PS)
- Harvard University (US)
- German Cancer Research Center (DE)
- Universidade de São Paulo (BR)
- Yonsei University (KR)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Heidelberg University (DE)
- Peking Union Medical College Hospital (CN)
- Villa Maria Hospital (UG)
- University Hospital Heidelberg (DE)
- Samsung Medical Center (KR)
- Agostino Gemelli University Polyclinic (IT)
- Fred Hutch Cancer Center (US)
- Hospital Universitario de Torrejón (ES)
- National Hospital Organization Kyushu Cancer Center (JP)
- Universidad Europea (MX)
- MedSIR (Spain) (ES)
- Magee-Womens Hospital (US)
- Dana-Farber Cancer Institute (US)
- Vall d'Hebron Hospital Universitari (ES)
- Gilead Sciences (United States) (US)
- Ziekenhuisnetwerk Antwerpen Stuivenberg (BE)
- International Breast Cancer Study Group (CH)
- Sungkyunkwan University (KR)
- Universidad Europea de Madrid (ES)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-10-19
- DOI
- https://doi.org/10.1056/nejmoa2511734
- Citations
- 24
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 25.09